4-氯苯甲脒盐酸盐 | 14401-51-5

• 物质功能分类: 化学试剂 - 有机试剂 - 肟
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯苯甲脒盐酸盐
• 中文别名: 对氯苯甲脒盐酸盐
• 英文名称: 4-chlorobenzamidine hydrochloride
• 英文别名: 4-chlorobenzimidamide hydrochloride；4-chlorobenzene-1-carboximidamide hydrochloride；p-chlorobenzamidine hydrochloride；Benzenecarboximidamide, 4-chloro-, hydrochloride (1:1)；4-chlorobenzenecarboximidamide;hydron;chloride
• CAS: 14401-51-5
• 化学式: C₇H₇ClN₂*ClH
• mdl: MFCD00126401
• 分子量: 191.06
• InChiKey: RXAOGVQDNBYURA-UHFFFAOYSA-N

物化性质

• 熔点：
  244 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.9
• 氢给体数：
  3
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2925290090
• WGK Germany：
  3
• 储存条件：
  | 2-8°C |

SDS

Name:	4-Chlorobenzene-1-carboximidamide hydrochloride 95+% Material Safety Data Sheet
Synonym:	4-Chlorobenzamidine hydrochlorid
CAS:	14401-51-5

Section 1 - Chemical Product MSDS Name:4-Chlorobenzene-1-carboximidamide hydrochloride 95+% Material Safety Data Sheet
Synonym:4-Chlorobenzamidine hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14401-51-5	4-Chlorobenzene-1-carboximidamide hydr	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 14401-51-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 245 - 247 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8Cl2N2
Molecular Weight: 191

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, ammonia.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14401-51-5: CV6136200 LD50/LC50:
Not available.
Carcinogenicity:
4-Chlorobenzene-1-carboximidamide hydrochloride - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 14401-51-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 14401-51-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 14401-51-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-氯苯甲脒盐酸盐可作为有机合成中间体和医药中间体，在实验室研发及化工医药生成过程中广泛应用。

制备该物质时，在室温条件下，将0.1摩尔对氯苯甲腈与100毫升无水乙醇加入250毫升四口瓶中，开启搅拌器。大约15分钟后，对氯苯甲腈完全溶解；随后加入氨基钠以防止其在空气中氧化。称量好的氨基钠置于封闭的试剂瓶内分批加入，待全部加入后反应14小时。之后，一次性加入0.1摩尔氯化铵并升温至60℃继续反应2小时。

完成反应后，趁热进行真空抽滤，并将滤液用盐酸调节pH值至1~2之间。接着使用带有真空泵的旋转蒸发仪，在0.085兆帕的真空度下对滤液进行减压蒸馏回收溶剂。剩余部分乙醇倒入表面皿中风干，得到淡黄色固体。将此固体放入烘箱内于82℃烘干12小时后研磨并装入自封袋保存，收率约为85%左右。

反应信息

• 作为反应物：
  描述：

  4-氯苯甲脒盐酸盐 生成 对氯苯甲腈
  参考文献：
  名称：

  Synthesis of the sym-Triazine System. II.¹ Preparation of Monosubstituted sym-Triazines by Reaction of sym-Triazine with Amidines

  摘要：

  DOI：

  10.1021/ja01515a047
• 作为产物：
  描述：

  对氯苯甲腈 在 氯化铵 作用下， 以 甲醇 为溶剂， 反应 72.0h， 生成 4-氯苯甲脒盐酸盐
  参考文献：
  名称：

  以碳化钙为炔烃源通过A3-偶联环化构建5-甲基-2,4-二芳基-1H-咪唑

  摘要：

  咪唑衍生物是合成药物、荧光材料和配体的关键组成部分。尽管开发了许多策略，但 2,4,5-取代咪唑的可靠合成仍在大量研究中。在这项研究中，我们提出了一种合成 2,4,5-取代咪唑甲基的方案，使用 A3 偶联环化与碳化钙作为乙炔源，与脒和醛反应。该方法具有几个特点，包括使用固体炔烃源、易于获取的起始材料以及对 34 个示例的适用性。

  DOI：

  10.1002/adsc.202300221

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• 一种含烷基和芳基嘧啶类化合物的合成方法
  申请人：新乡医学院

  公开号：CN111362880B

  公开（公告）日：2023-01-13

  本发明公开了一种含烷基和芳基嘧啶类化合物的合成方法，属于有机合成技术领域。本发明的技术方案要点为：一种含烷基和芳基嘧啶类化合物的合成方法，具体步骤为：将醛类化合物、脒盐酸盐类化合物和三级脂肪胺类化合物溶于溶剂中，再加入碘试剂和氧化剂，然后于110‑150℃反应制得目标产物含烷基和芳基嘧啶类化合物。本发明合成过程简单高效，通过无过渡金属催化的一锅串联反应一步直接制得嘧啶类化合物，避免了由于多步反应中多种试剂的使用以及对各步反应中间体的纯化处理等引起的资源浪费和环境污染，合成过程操作方便，原料简单，反应条件温和，底物适用范围广，同时以三级脂肪胺类化合物为原料巧妙地引入烷基取代基。
• An I₂-mediated aerobic oxidative annulation of amidines with tertiary amines<i>via</i>C–H amination/C–N cleavage for the synthesis of 2,4-disubstituted 1,3,5-triazines
  作者：Yizhe Yan、Zheng Li、Chang Cui、Hongyi Li、Miaomiao Shi、Yanqi Liu

  DOI：10.1039/c8ob00635k

  日期：——

  An iodine-mediated formal oxidative cycloaddition of amidines with tertiary amines was first demonstrated in air. Both symmetrical and unsymmetrical 2,4-disubstituted 1,3,5-triazines were obtained in up to 85% yields. It is noted that a tertiary amine was employed as a one carbon synthon of 1,3,5-triazines and two C–N bonds were formed in one pot. Control experiments revealed that the reaction underwent

  碘在空气中首次证明了碘与叔胺介导的甲醛氧化环加成反应。对称和不对称的2,4-二取代的1,3,5-三嗪均以高达85％的产率获得。注意，叔胺被用作1,3,5-三嗪的一个碳合成子，并且在一个罐中形成了两个C–N键。对照实验表明，该反应经历了由I +促进的自由基途径。该方法是无过渡金属，无过氧化物的，并且操作简便，可在多种基材上实施。
• Iridium-catalyzed cascade dehydrogenation, ring-closure reaction leading to 2,4,6-triaryl-1,3,5-triazines
  作者：Gang Shi、Fei He、Youxin Che、Caihua Ni、Ying Li

  DOI：10.1134/s1070363216020304

  日期：2016.2

  An efficient iridium-catalyzed dehydrogenation, ring-closure reaction, has been developed via a cascade sequence, in which [Cp*IrI2]2/Xantphos proved to be the most efficient catalyst for the synthesis of 2,4,6-triaryl-1,3,5-triazines from stable aryl-substituted alcohols and amidines. It was the first case of iridium catalyst successful application in such transformation.

  通过级联序列开发了一种有效的铱催化的脱氢，闭环反应，其中[Cp * IrI 2 ] 2 / Xantphos被证明是合成2,4,6-三芳基-的最有效催化剂。来自稳定的芳基取代的醇和am的1,3,5-三嗪 这是铱催化剂成功应用于此类转化的第一种情况。
• Pyrimidine A2b selective antagonist compounds, their synthesis and use
  申请人：——

  公开号：US20030162764A1

  公开（公告）日：2003-08-28

  The subject invention provides compounds having the structure: 1 wherein R 1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R 2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R 3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 2 and R 3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R 3 is oxygen; R 4 and R 5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)—O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 4 NR 5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R 12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A 2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.

  本发明提供具有以下结构的化合物： 1 其中R 1 是取代或未取代的苯基或含1至5个杂原子的5-6元杂环或杂芳环；R 2 是氢，或取代或未取代的烷基，—C(O)-烷基，—C(O)—O-烷基，烷氧基，环烷基，烯丙基，单环或双环芳基，杂芳基或杂环部分；R 3 是氢，或取代或未取代的烷基，—C(O)-烷基，—C(O)—O-烷基，烷氧基，环烷基，烯丙基，单环或双环芳基，杂芳基或杂环部分，或者R 2 和R 3 连接形成一个杂环；其中虚线代表可能存在或不存在第二键，当存在时R 3 是氧；R 4 和R 5 各自独立地是取代或未取代的烷基，—C(O)-烷基，—C(O)—O-烷基，烷氧基，环烷基，烯丙基，单环或双环芳基，杂芳基或杂环部分，或者R 4 和R 5 共同形成一个含1至6个杂原子的取代或未取代的单环或双环杂环或杂芳基部分；R 12 是氢，烷基，卤素或腈；且n是0，1，2，3或4，或其对应的手性体，或特定的互变异构体，或其药物可接受的盐，以及通过给药治疗与A 2b 腺苷受体相关疾病的方法。